KalVista Pharmaceuticals, Inc. 8-K

What Happened

• On March 25, 2026, KalVista Pharmaceuticals, Inc. announced and furnished a press release reporting its results of operations and financial condition for the eight‑month transition period ended December 31, 2025 (Item 2.02 of Form 8-K). The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: March 25, 2026 (Form 8-K, Item 2.02).
• Reporting period: eight‑month transition period ended December 31, 2025.
• Disclosure format: press release furnished as Exhibit 99.1; Inline XBRL cover page included (Exhibit 104).
• No other items (e.g., executive changes or transactions) were reported in this 8-K.

Why It Matters

• This 8-K provides the company’s latest reported financial results (earnings/revenue and broader financial condition) for a nonstandard eight‑month reporting period, which may affect year‑over‑year or quarterly comparisons.
• Retail investors should read the attached press release and subsequent SEC filings for the detailed figures (revenue, net income or loss, cash position and any guidance) to assess KalVista’s performance and liquidity.